TY - JOUR
T1 - Eslicarbazepine acetate response in intellectual disability population versus general population
AU - Allard, Jon
AU - Lawthom, Charlotte
AU - Henley, William
AU - Mclean, Brendan
AU - Hudson, Sharon
AU - Tittensor, Phil
AU - Rajakulendran, Sanjeev
AU - Ellawela, Shan
AU - Pace, Adrian
AU - Shankar, Rohit
N1 - Publisher Copyright:
© 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd
PY - 2021/3
Y1 - 2021/3
N2 - Background: A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescribing of antiepileptic drugs (AEDs) for those with ID is, however, limited. Aims of Study: This study seeks to strengthen the research evidence around Eslicarbazepine Acetate (ESL), a new AED, by comparing response of individuals with ID to those from the general population who do not have ID. Methods: A single data set was created through retrospective data collection from English and Welsh NHS Trusts. The UK-based Epilepsy Database Research Register (Ep-ID) data collection and analysis method were used. Results: Data were collected for 93 people (36 ID and 57 ‘no ID’). Seizure improvement of ‘>50%’ was higher at 12 months for ‘no ID’ participants (56%), compared to ID participants (35%). Retention rates were slightly higher for those with ID (56% compared to 53%). Neither difference was significant. Conclusions: Tolerance and Efficacy for ID and ‘no ID’ people in our data set were similar. Seizure improvement and retention rates were slightly lower than that found in other European data sets, but findings strengthen the evidence for the use of ESL in the ID population.
AB - Background: A quarter of people with intellectual disability (ID) have epilepsy, compared to approximately one in a hundred across the general population. Evidence for the safe and effective prescribing of antiepileptic drugs (AEDs) for those with ID is, however, limited. Aims of Study: This study seeks to strengthen the research evidence around Eslicarbazepine Acetate (ESL), a new AED, by comparing response of individuals with ID to those from the general population who do not have ID. Methods: A single data set was created through retrospective data collection from English and Welsh NHS Trusts. The UK-based Epilepsy Database Research Register (Ep-ID) data collection and analysis method were used. Results: Data were collected for 93 people (36 ID and 57 ‘no ID’). Seizure improvement of ‘>50%’ was higher at 12 months for ‘no ID’ participants (56%), compared to ID participants (35%). Retention rates were slightly higher for those with ID (56% compared to 53%). Neither difference was significant. Conclusions: Tolerance and Efficacy for ID and ‘no ID’ people in our data set were similar. Seizure improvement and retention rates were slightly lower than that found in other European data sets, but findings strengthen the evidence for the use of ESL in the ID population.
KW - epilepsy
KW - Eslicarbazepine acetate
KW - intellectual disability
KW - UK Ep-ID research database register
UR - http://www.scopus.com/inward/record.url?scp=85096785338&partnerID=8YFLogxK
UR - https://pearl.plymouth.ac.uk/context/pms-research/article/2177/viewcontent/Eslicarbazepine_Acetate_response_in_Intellectual_D.pdf
U2 - 10.1111/ane.13368
DO - 10.1111/ane.13368
M3 - Article
C2 - 33131083
AN - SCOPUS:85096785338
SN - 0001-6314
VL - 143
SP - 256
EP - 260
JO - Acta Neurologica Scandinavica
JF - Acta Neurologica Scandinavica
IS - 3
ER -